Organon & Co. (OGN): Net Income
$187.00M
Year ended 2025-12-31
$209.00M
Trailing 12 months to 2026-06-30
-41.1%
3-year compound annual growth
-38.7%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $187.00M | -78.4% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $864.00M | -15.5% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $1.02B | +11.6% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $917.00M | -32.1% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $1.35B | -37.5% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $2.16B | -32.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $3.22B | n/a | 2022-03-21, From 2019-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $187.00M | -78.4% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $286.93M | n/m |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | -$232.00M | n/m |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | -$356.15M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | -$1.43B | n/m |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.67B | +7.5% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $120.00M | n/m |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $313.75M | n/m |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $348.90M | -18.3% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗